These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8726012)

  • 21. Antimicrobial Susceptibility Patterns of
    Assaidi A; Ellouali M; Latrache H; Timinouni M; Zahir H; Karoumi A; Barguigua A; Mliji EM
    Microb Drug Resist; 2020 Aug; 26(8):991-996. PubMed ID: 32125920
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
    Renaudin H; Bébéar C
    Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):838-41. PubMed ID: 1964899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. WIN 57273 is bactericidal for Legionella pneumophila grown in alveolar macrophages.
    Edelstein PH; Edelstein MA
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2132-6. PubMed ID: 2619277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Susceptibility of Legionella pneumophila to eight antimicrobial agents including four macrolides under different assay conditions.
    Liebers DM; Baltch AL; Smith RP; Hammer MC; Conroy JV
    J Antimicrob Chemother; 1989 Jan; 23(1):37-41. PubMed ID: 2526110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of lomefloxacin (NY-198 or SC 47111), ciprofloxacin, and erythromycin against 100 clinical Legionella strains.
    Edelstein PH; Gaudet EA; Edelstein MA
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):93S-95S. PubMed ID: 2791505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular susceptibility testing in HL-60 cells.
    Stout JE; Arnold B; Yu VL
    J Antimicrob Chemother; 1998 Feb; 41(2):289-91. PubMed ID: 9533475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Susceptibilities of Legionella spp. to newer antimicrobials in vitro.
    Schülin T; Wennersten CB; Ferraro MJ; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 1998 Jun; 42(6):1520-3. PubMed ID: 9624509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Antimicrobial susceptibility patterns of Legionella isolates in the environment and in patients].
    Choi GE; Kang JE; Lee EY; Chang CL; Tateda K; Yamaguchi K; Kim KH; Kim JM
    Korean J Lab Med; 2010 Feb; 30(1):28-33. PubMed ID: 20197719
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergy and antagonism of combinations with quinolones.
    Neu HC
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):255-61. PubMed ID: 1864285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of sparfloxacin (CI-978; AT-4140) for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.
    Edelstein PH; Edelstein MA; Weidenfeld J; Dorr MB
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2122-7. PubMed ID: 2073101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with Legionella pneumophila pneumonia.
    Edelstein PH; Edelstein MA
    Antimicrob Agents Chemother; 1999 Jan; 43(1):90-5. PubMed ID: 9869571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli.
    Critchley IA; Sahm DF; Kelly LJ; Karlowsky JA
    Chemotherapy; 2003 May; 49(1-2):44-8. PubMed ID: 12714810
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.
    Critchley IA; Jones ME; Heinze PD; Hubbard D; Engler HD; Evangelista AT; Thornsberry C; Karlowsky JA; Sahm DF
    Clin Microbiol Infect; 2002 Apr; 8(4):214-21. PubMed ID: 12047413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.
    Visalli MA; Bajaksouzian S; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1475-81. PubMed ID: 9210669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of the synergic effects of aminoglycoside-fluoroquinolone and third-generation cephalosporin combinations against clinical isolates of Pseudomonas spp.
    Mayer I; Nagy E
    J Antimicrob Chemother; 1999 May; 43(5):651-7. PubMed ID: 10382886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Susceptibility of Legionella species to antimicrobial agents.
    Chen SC; Paul ML; Gilbert GL
    Pathology; 1993 Apr; 25(2):180-3. PubMed ID: 8367199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of various antibiotics against clinical strains of Legionella species isolated in Japan.
    Miyashita N; Kobayashi I; Higa F; Aoki Y; Kikuchi T; Seki M; Tateda K; Maki N; Uchino K; Ogasawara K; Kurachi S; Ishikawa T; Ishimura Y; Kanesaka I; Kiyota H; Watanabe A
    J Infect Chemother; 2018 May; 24(5):325-329. PubMed ID: 29459000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolone, macrolide and other antimicrobial agents.
    Kitsukawa K; Hara J; Saito A
    J Antimicrob Chemother; 1991 Mar; 27(3):343-53. PubMed ID: 2037540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.
    Hoffner SE; Gezelius L; Olsson-Liljequist B
    J Antimicrob Chemother; 1997 Dec; 40(6):885-8. PubMed ID: 9462443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contemporary in vitro synergy rates for aztreonam combined with newer fluoroquinolones and beta-lactams tested against gram-negative bacilli.
    Sader HS; Huynh HK; Jones RN
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):547-50. PubMed ID: 14596974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.